Author
Listed:
- A. Cleynen
(CNRS, Univ. Montpellier)
- R. Szalat
(Harvard Medical School)
- M. Kemal Samur
(Harvard Medical School
Institute, Harvard Medical School)
- S. Robiou du Pont
(IUC-Oncopole, and CRCT INSERM U1037)
- L. Buisson
(IUC-Oncopole, and CRCT INSERM U1037)
- E. Boyle
(IUC-Oncopole, and CRCT INSERM U1037)
- M. L. Chretien
(CHU Dijon)
- K. Anderson
(Harvard Medical School)
- S. Minvielle
(CHU Nantes)
- P. Moreau
(CHU Nantes)
- M. Attal
(IUC-Oncopole, and CRCT INSERM U1037)
- G. Parmigiani
(Harvard Medical School
Institute, Harvard Medical School)
- J. Corre
(IUC-Oncopole, and CRCT INSERM U1037)
- N. Munshi
(Harvard Medical School
VA Boston Healthcare System)
- H. Avet-Loiseau
(IUC-Oncopole, and CRCT INSERM U1037)
Abstract
Multiple myeloma is a plasma cell malignancy characterized by recurrent IgH translocations and well described genomic heterogeneity. Although transcriptome profiles in multiple myeloma has been described, landscape of expressed fusion genes and their clinical impact remains unknown. To provide a comprehensive and detailed fusion gene cartography and suggest new mechanisms of tumorigenesis in multiple myeloma, we performed RNA sequencing in a cohort of 255 newly diagnosed and homogeneously treated multiple myeloma patients with long follow-up. Here, we report that patients have on average 5.5 expressed fusion genes. Kappa and lambda light chains and IgH genes are main partners in a third of all fusion genes. We also identify recurrent fusion genes that significantly impact both progression-free and overall survival and may act as drivers of the disease. Lastly, we find a correlation between the number of fusions, the age of patients and the clinical outcome, strongly suggesting that genomic instability drives prognosis of the disease.
Suggested Citation
A. Cleynen & R. Szalat & M. Kemal Samur & S. Robiou du Pont & L. Buisson & E. Boyle & M. L. Chretien & K. Anderson & S. Minvielle & P. Moreau & M. Attal & G. Parmigiani & J. Corre & N. Munshi & H. Ave, 2017.
"Expressed fusion gene landscape and its impact in multiple myeloma,"
Nature Communications, Nature, vol. 8(1), pages 1-10, December.
Handle:
RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-00638-w
DOI: 10.1038/s41467-017-00638-w
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-00638-w. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.